Cancer/testis antigen 1 (ORF2 (14-33))

Cancer/testis antigen 1 (ORF2 (14-33)) is a synthetic peptide fragment derived from the cancer/testis antigen 1 (CTAG1), also known as NY-ESO-1. As a highly immunogenic segment of the larger protein, this peptide encompasses amino acids 14 to 33 of the ORF2 region, representing a sequence frequently investigated in tumor immunology and antigen presentation studies. Its unique expression profile—restricted in normal tissues but prevalent in a variety of malignancies—renders it a valuable tool for research focused on tumor antigenicity, immune recognition, and peptide-based screening. The precise definition of this peptide segment allows for controlled experimental design in studies of T-cell epitope mapping, antigen processing, and immune response characterization.

Epitope mapping: The 14-33 fragment of CTAG1 is widely utilized in mapping immunodominant epitopes recognized by cytotoxic T lymphocytes and helper T cells. By exposing immune cells to this defined peptide sequence, researchers can delineate which regions of the antigen are critical for immune recognition. This application is essential for understanding T-cell receptor specificity and the molecular basis of antigen-driven immune responses, particularly in the context of tumor immunology where CTAG1 serves as a prototypical cancer/testis antigen.

Antigen presentation studies: The peptide's defined sequence and immunogenic properties make it a prime candidate for examining the mechanisms of antigen processing and presentation by major histocompatibility complex (MHC) molecules. Investigators frequently employ the 14-33 fragment to study peptide loading onto MHC class I and II molecules, assess peptide stability, and evaluate the efficiency of antigen presentation pathways in both normal and neoplastic cells. These studies contribute to elucidating the determinants of immunodominance and the efficiency of immune surveillance in cancer.

Immunogenicity assays: The CTAG1 (ORF2 (14-33)) peptide is commonly used in functional assays to evaluate the immunogenic potential of candidate tumor antigens. In vitro stimulation of peripheral blood mononuclear cells (PBMCs) or T-cell clones with this peptide enables quantification of cytokine release, proliferation, and cytolytic activity. Such assays are instrumental in preclinical research aimed at identifying strong immunogenic epitopes and optimizing peptide-based immunological reagents for monitoring immune responses in experimental settings.

Peptide-based screening: The defined sequence of this synthetic peptide supports its use in high-throughput screening platforms designed to identify T-cell receptors, antibodies, or peptide-MHC complexes with specificity for CTAG1. Screening libraries or arrays incorporating the 14-33 fragment allow for rapid assessment of immune repertoire diversity, binding affinity, and antigen-specific recognition, thereby facilitating the discovery of novel immune targets and the development of research tools for cancer immunology.

Biochemical characterization: Beyond immunological applications, the peptide serves as a model substrate for studying peptide-protein interactions, structural motifs, and post-translational modifications relevant to the CTAG1 protein. Its use in biophysical assays, such as surface plasmon resonance or nuclear magnetic resonance studies, enables detailed analysis of binding kinetics, conformational dynamics, and molecular recognition events. Such investigations provide foundational insights into the structural biology of cancer/testis antigens and inform the rational design of peptide-based reagents for advanced research applications.

1. Oleic acid and glucose regulate glucagon-like peptide 1 receptor expression in a rat pancreatic ductal cell line

2. Effect of Short-Term Desiccation, Recovery Time, and CAPA-PVK Neuropeptide on the Immune System of the Burying Beetle Nicrophorus vespilloides

3. Implications of ligand-receptor binding kinetics on GLP-1R signalling

4. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis

5. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging